The promising description of a potential basis for gene therapy in treating HIV infection does not mean that traditional approaches should be abandoned (pages 667–673).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Larder, B.A. & Kemp, S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155–1157 (1989).
St. Clair, M.H. et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253, 1557–1559 (1991).
Maciejewski, J.P. et al. Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nature Med. 1, 667–673 (1995).
Zack, J.A. et al. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 61, 213–222 (1990).
Wu, J., Amandoron, E., Li, X., Wainberg, M.A. & Parniak, M.A. Monoclonal antibody-mediated inhibition of HIV-1 reverse transcriptase polymerase activity. J. biol. Chem. 268, 9980–9985 (1993).
Skalka, A.M. & Goff, S.P. (eds). Reverse Transcriptase (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1993).
Martin, J.L., Wilson, J.E., Haynes, R.L. & Furman, P.A. Mechanism of resistance of human immunodeficiency virus type 1 to 2′,3′-dideoxyinosine. Proc. natn. Acad. Sci. U.S.A. 90, 6135–6139 (1993).
Gu, Z., Arts, E.J., Parniak, M.A. & Wainberg, M.A. Mutated K65R recombinant HIV-1 reverse transcriptase shows diminished chain termination in the presence of 2′,3′-dideoxycytidine and 5′-triphosphate and other drugs. Proc. natn. Acad. Sci. U.SA. 92, 2760–2764 (1995).
Katlama, C., The European Lamivudine HIV Working Group. Combination 3TC (lamivudine) ZDV (zidovudine) vs ZDV monotherapy in ZDV naive HIV-1 positive patients with CD4 of 100–400 cells/mm3. AIDS 8, S6 Abstract 7.5 (1994).
Staszewski, S., Lamivudine HIV Working Group. Combination 3TC (lamivudine) ZDV (zidovudine) vs ZDV monotherapy in ZDV pre-treated HIV-1 positive patients with CD4 of 100–400 cells/mm3. AIDS 8, S7 Abstract 7.6 (1994).
Gu, Z., Gao, Q., Li, X., Parniak, M.A. & Wainberg, M.A. A novel mutation in the human immunodeficiency virus type 1 reverse transcriptase that encodes resistance to 2′,3′-dideoxyinosine and cross-resistance to 2′,3′-dideoxycytidine. J. Virol. 66, 7128–7135 (1992).
Schinazi, R.F. et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37, 875–881 (1993).
Tisdale, M., Kemp, S.D., Parry, N.R. & Larder, B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistance to 3′-thiacyti-dine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. natn. Acad. Sci. U.S.A. 90, 5653–5656 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wainberg, M., Gu, Z. Targeting HIV reverse transcriptase in novel ways. Nat Med 1, 628–629 (1995). https://doi.org/10.1038/nm0795-628
Issue Date:
DOI: https://doi.org/10.1038/nm0795-628
